跳至主要内容
临床试验/NCT07796178
NCT07796178招募中4 期

Evaluation of Lacrifill Treatment for Alleviating Dry Eye Symptoms in Post-Operative Cataract Surgery Subjects

Eye Research Associates, LLC2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年9月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
40
试验地点
2
主要终点
OSDI Scores at the 1-month post-operative visit compared to pre-treatment (0-100 scale)

研究概览

简要总结

Dry Eye Disease is defined as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.' 'By the The Tear Film and Ocular Surface Society. Despite there being a number of factors that impact DED however one factor that has been considered likely is that of a complication from ocular surgery itself. Which can cause both corneal nerve, and ocular surface damage. Therefore this study aims to determine how Lacrfill performs in preventing post-operative dry eye symptoms in those who have recently had unilateral cataract surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Investigator)

盲法说明

The Principal Investigator who is completing the assessments will be masked in order to prevent biasing the study. An unmasked coordinator not involved in the assessment portion of the study will provide information to the study participant regarding the treatment and be in charge of the randomziation.

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adults ≥18 years of age.
  • •Have the potential of 20/40 visual acuity or better post-cataract surgery.
  • •have cataract surgery scheduled for both eyes
  • •Corneal staining score of ≥3 on the original National Eye Institute (NEI; 0-15 total score) staining scale in the study eye.
  • •willing to discontinue contact lens throughout the study?
  • •pre-treatment OSDI scores of ≤12 (asymptomatic)?

排除标准

  • •Known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome)?
  • •History of ocular surgery within the past 12 months (excluding cataract surgery)
  • •Anticipated complications from cataract surgery in either eye?
  • •History of severe ocular trauma, active ocular infection or inflammation that is not dry eye-related?
  • •Used Accutane or is currently using ocular medications/treatments outside of study treatments? Artificial tears will be allowed.
  • •Physical meibomian gland treatment withing 1 month of enrollment?
  • •Having any conditions or are in a situation, which in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study.
  • •Currently pregnant or breast feeding

研究组 & 干预措施

Lacrifill

Experimental

Qualifying subjects will be treated with Lacrifill via the manufacturer's instructions

干预措施: Lacrifill (Drug)

Saline/Standard of care

Active Comparator

Qualifying subjects will be treated with saline via the manufacturer's instructions

干预措施: Saline (Drug)

结局指标

主要结局

OSDI Scores at the 1-month post-operative visit compared to pre-treatment (0-100 scale)

时间窗: 1-month post operative compared to pre-treatment

Ocular Surface Disease Index scores will be determined on a scale with higher scores meaning more discomfort.

次要结局

  • Eye Dryness visual analog scale (VAS) Scores 1 month post operative(1 month post operative as compared to pre-treatment.)
  • Eye Dryness visual analog scale (VAS) Scores 3 month post operative(3 month post operative as compared to pre-treatment.)
  • • OSDI Scores at the 3-month post-operative visit compared to pre-treatment (0-100 scale).(pre-treatment as compared to 3 months post operative.)

研究者

发起方
Eye Research Associates, LLC
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

尚未招募
2/3 期
Manjishtadi Anjana For Shushkakshipak (Dry Eye Disease)Diseases of the eye and adnexa, (2) ICD-10 Condition: H578||Other specified disorders of eye and adnexa. Ayurveda Condition: Dryey, (3) ICD-10 Condition: H578||Other specified disorders of eye and adnexa. Ayurveda Condition: Shusk, (4) ICD-10 Condition: H578||Other specified disorders of eye and adnexa. Ayurveda Condition: SARVAGATAKSHIROGAH, (5) ICD-10 Condition: H579||Unspecified disorder of eye and adnexa,
CTRI/2025/12/099130Dr Sneha Raju Pujari76
尚未招募
2/3 期
This clinical trial will be performed to understand the efficacy of Yashtimadhu Siddha Taila Nasya with Carboxy Methylcellulose Eye Drop in Dry Eye Syndrome which includes the symptoms such as Irritation or Foreign body sensation in eyes, Dryness, Itching, Blurry vision, Excessive blinking etc.Disorder of lacrimal system, unspecified. Ayurveda Condition: NETRAROGAH/AKSHIROGAH,
CTRI/2026/02/103243PDEAs College of Ayurved and Research Centre60
招募中
不适用
Detection and Optimization of Treatment of Severe Cases of Dry Eye DiseaseDry Eye
NCT07554911Singapore National Eye Centre200
尚未招募
2/3 期
This clinical trial will be performed to understand the add-on effect of Bhringarajaadi tail Nasya with carboxymethylcellulose eye drops in the management of Dry Eye Syndrome.Disorder of lacrimal system, unspecified. Ayurveda Condition: NETRAROGAH/AKSHIROGAH,
CTRI/2024/11/076981PDEAs college of ayurved and research centre60
尚未招募
4 期
Comparing lifitegrast 5 percentage and cyclosporine 0.05 percentage eyedrops for treating moderate to severe dry eye disease.Disorder of lacrimal system, unspecified, (2) ICD-10 Condition: H041||Other disorders of lacrimal gland,
CTRI/2025/12/098542Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences70
Evaluation of Lacrifill | 临床试验